Page last updated: 2024-12-09

desonide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Desonide: A nonfluorinated corticosteroid anti-inflammatory agent used topically for DERMATOSES. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

desonide : Triamcinolone acetonide with hydrogen instead of the fluorine substituent at position 9. A corticosteroid anti-inflammatory, it is used topically as a cream, ointment or lotion for the treatment of various skin disorders. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5311066
CHEMBL ID1201109
CHEBI ID204734
SCHEMBL ID3631
MeSH IDM0006084

Synonyms (112)

Synonym
AB01274712-01
desonide (usp/inn)
638-94-8
verdeso (tn)
desowen (tn)
D03696
sterax
verdeso
16-alpha-hydroxyprednisole-16,17-acetonide
desonate
topifug
einecs 211-351-6
11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone
steroderm
desonida [inn-spanish]
pregna-1,4-diene-3,20-dione, 11,21-dihydroxy-16,17-((1-methylethylidene)bis(oxy))-, (11beta,16alpha)-
locapred
desonidum [inn-latin]
d 2083
desowen
desonide [usan:inn:ban]
flusemidon
prednacinolone
tridesonit
prednisolone-16,17-acetonide, 16-alpha-hydroxy-
hamiltoderm
d-2083
desilux
reticus
apolar
zotinar
desonide
11beta,21-dihydroxy-16alpha,17-[(1-methylethylidene)bis(oxy)]pregna-1,4-diene-3,20-dione
11beta,21-dihydroxy-16alpha,17alpha-isopropylidenedioxypregna-1,4-diene-3,20-dione
16alpha-hydroxyprednisole-16,17-acetonide
16alpha-hydroxyprednisolone-16alpha,17-acetonide
16alpha,17alpha-isopropylidenedioxyprednisolone
desfluorotriamcinolone acetonide
DB01260
11beta,21-dihydroxy-16alpha,17-isopropylidenedioxypregna-1,4-diene-3,20-dione
NCGC00167983-01
tridesilon
CHEMBL1201109
nsc-759226
d2083 ,
desonidum
chebi:204734 ,
desonida
(4ar,4bs,5s,6as,6bs,9ar,10as,10bs)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2h-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
dtxcid5026756
dtxsid7046756 ,
cas-638-94-8
tox21_112603
unii-j280872d1o
j280872d1o ,
nsc 759226
S1701
gtpl7066
desonide component of tridesilon
desonide [usp impurity]
budesonide impurity f [ep impurity]
desonide [vandf]
tridesilon component desonide
desonide [mart.]
desonide [mi]
desonide [who-dd]
desonide [inn]
desonide [usp monograph]
pregna-1,4-diene-3,20-dione, 11,21-dihydroxy-16,17-((1-methylethylidene)bis(oxy))-, (11.beta.,16.alpha.)-
desonide [orange book]
desonide [usp-rs]
desonide [usan]
CCG-221279
HY-B0248
WBGKWQHBNHJJPZ-LECWWXJVSA-N
SCHEMBL3631
NCGC00274065-01
tox21_112603_1
Q-101382
AB01274712_02
(1s,2s,4r,8s,9s,11s,12s,13r)-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.0^{2,9}.0^{4,8}.0^{13,18}]icosa-14,17-dien-16-one
(1s,2s,4r,8s,9s,11s,12s,13r)-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one
HMS3715P20
16alpha,17-[1-methylethylidenebis(oxy)]-11beta,21-dihydroxypregna-1,4-diene-3,20-dione (desonide)
budesonide imp. f (ep); desonide; 16alpha,17-[1-methylethylidenebis(oxy)]-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; budesonide impurity f
BCP04201
F20496
mfcd00866151
AS-13892
Q904011
BRD-K21528677-001-03-6
AKOS037643323
16alpha-hydroxyprednisolone acetonide
(11beta,16alpha)-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]pregna -1,4-diene-3,20-dione
D5578
desonidum (inn-latin)
lokara
d07ab08
desonida (inn-spanish)
tridesilon cream
s01ba11
desonide (mart.)
desonide (usp impurity)
budesonide impurity f (ep impurity)
desonide (usp-rs)
desrx
desonide (usp monograph)
(4ar,4bs,5s,6as,6bs,9ar,10as,10bs)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2h-naphtho(2',1':4,5)indeno(1,2-d)(1,3)dioxol-2-one
desonide ointment, 0.05%
desonide 0.05%
EN300-7361932
dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-pregna-1,4-diene-3,20-dione

Research Excerpts

Toxicity

6% of participants in the desonide foam group and 14% in the vehicle foam group reported adverse events.

ExcerptReferenceRelevance
" The safety of the drugs was assessed by identification of any side effects or adverse events of any kind."( Efficacy and safety of desonide phosphate for the treatment of allergic conjunctivitis.
Leonardi, A; Milazzo, G; Papa, V; Secchi, AG, 2002
)
0.31
" This paper provides information on its safety record, as determined from adverse event reports and published trial results."( Overview on desonide 0.05%: a clinical safety profile.
Fuchs, B; Lebwohl, M; Wong, VK,
)
0.13
" The phase II and III clinical efficacy studies evaluated adverse events."( Desonide foam 0.05%: safety in children as young as 3 months.
Hebert, AA, 2008
)
0.35
" The combined safety data from the phase II and III studies revealed 6% of participants in the desonide foam group and 14% in the vehicle foam group reported adverse events (P = ."( Desonide foam 0.05%: safety in children as young as 3 months.
Hebert, AA, 2008
)
0.35
"Desonide foam was safe and well tolerated in participants as young as 3 months."( Desonide foam 0.05%: safety in children as young as 3 months.
Hebert, AA, 2008
)
0.35
" DES NE-GEL has a significant curative effect on dermatitis/eczema in a mouse model and is expected to provide a new, efficient, and low toxic preparation for clinical treatment of dermatitis/eczema through the percutaneous system."( Desonide Nanoemulsion Gel for Transdermal Absorption Drug Delivery: Pharmacodynamic and Safety Evaluation.
Chen, Y; Huang, L; Lin, H; Liu, H; Ma, Q; Yao, Y; Zhang, J, 2023
)
0.91

Compound-Compound Interactions

ExcerptReferenceRelevance
"To observe and analyze the clinical efficacy of mucopolysaccharide polysulfate (MPS) ointment combined with desonide ointment in treatment of infantile eczema."( Clinical efficacy of mucopolysaccharide polysulfate ointment combined with desonide ointment in treatment of infantile eczema.
Dang, Y; Jia, Y; Yang, L; Zhu, D, 2019
)
0.51

Bioavailability

ExcerptReferenceRelevance
" This indicates that in vitro data can be useful in predicting oral bioavailability of GCS."( Effect of structural alterations on the biotransformation rate of glucocorticosteroids in rat and human liver.
Andersson, P; Lihné, M; Ryrfeldt, A; Thalén, A, 1987
)
0.27
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" In general, the degree of suppression of the HPA axis function is related to the daily dosage of steroid given, the duration of its administration, the extent of body surface covered, and the potency of the corticosteroid."( Effect of desonide ointment, 0.05%, on the hypothalamic-pituitary-adrenal axis of children with atopic dermatitis.
Baker, MD; Czernielewski, JM; Dolak, TM; Grote, GD; Herndon, JH; Lucky, AW; Tuley, MR; Williams, JL, 1997
)
0.3
"Desonide is a topical corticoid used in the treatment of skin diseases and is marketed in different pharmaceutical dosage forms."( Investigation of the stabilizing effects of antioxidants and benzophenone-3 on desonide photostability.
Bueno Rolim, CM; de Bona da Silva, C; Horn Adams, AI; Rosa, P; Snovarski Salla, AP, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
anti-inflammatory drugA substance that reduces or suppresses inflammation.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (7)

ClassDescription
11beta-hydroxy steroidAny 11-hydroxy steroid in which the hydroxy group at position 11 has beta- configuration.
21-hydroxy steroid
20-oxo steroidAn oxo steroid carrying an oxo group at position 20.
corticosteroidA natural or synthetic analogue of the hormones secreted by the adrenal gland.
cyclic ketalA ketal in the molecule of which the ketal carbon and one or both oxygen atoms thereon are members of a ring.
3-oxo-Delta(1),Delta(4)-steroidA 3-oxo-Delta(1) steroid containing an additional double bond between positions 4 and 5.
primary alpha-hydroxy ketoneAn alpha-hydroxy ketone in which the carbonyl group and the hydroxy group are linked by a -CH2 (methylene) group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (16)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
SMAD family member 2Homo sapiens (human)Potency23.91450.173734.304761.8120AID1346859
SMAD family member 3Homo sapiens (human)Potency23.91450.173734.304761.8120AID1346859
TDP1 proteinHomo sapiens (human)Potency12.77810.000811.382244.6684AID686978; AID686979
AR proteinHomo sapiens (human)Potency0.01760.000221.22318,912.5098AID1259381; AID743040; AID743042; AID743054
progesterone receptorHomo sapiens (human)Potency0.14440.000417.946075.1148AID1346784; AID1347036
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency1.58490.01237.983543.2770AID1346984
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency0.02380.000214.376460.0339AID720691; AID720692; AID720719
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency0.00820.003041.611522,387.1992AID1159552; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency13.33320.001530.607315,848.9004AID1224841
pregnane X nuclear receptorHomo sapiens (human)Potency6.19690.005428.02631,258.9301AID1346982; AID1346985
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.20950.000229.305416,493.5996AID743079; AID743080; AID743091
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency13.33220.001024.504861.6448AID743215
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency0.01060.001723.839378.1014AID743083
nuclear receptor subfamily 1, group I, member 2Rattus norvegicus (Norway rat)Potency8.91250.10009.191631.6228AID1346983
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency0.01190.011917.942071.5630AID651632
Ataxin-2Homo sapiens (human)Potency0.01190.011912.222168.7989AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (18)

Processvia Protein(s)Taxonomy
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (10)

Processvia Protein(s)Taxonomy
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (21)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID188016Anti-inflammatory effect in rat granuloma assay, activity relative to hydrocortisone and hydrocortisone 21-acetate1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Structure-activity relationships in the antiinflammatory steroids: a pattern-recognition approach.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID91225Antiinflammatory activity measured by using McKenzie-Stoughton human vasoconstrictor assay; Potent1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Computer-aided studies of the structure-activity relationships between the structure of some steroids and their antiinflammatory activity.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID90218Potency relative to fluocinolone 16,17-acetonide(Experimental vasoconstictor activity) in human;NA =Not active1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Structure-activity relationships in the antiinflammatory steroids: a pattern-recognition approach.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (98)

TimeframeStudies, This Drug (%)All Drugs %
pre-199029 (29.59)18.7374
1990's10 (10.20)18.2507
2000's21 (21.43)29.6817
2010's32 (32.65)24.3611
2020's6 (6.12)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials29 (26.61%)5.53%
Reviews8 (7.34%)6.00%
Case Studies32 (29.36%)4.05%
Observational0 (0.00%)0.25%
Other40 (36.70%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (11)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
8-Week Atopic Dermatitis (AD) Treatment Study [NCT03386032]Phase 365 participants (Actual)Interventional2017-11-27Completed
Alterations in the Human Microbiome With Commonly Used Topical Medications [NCT03437005]Phase 124 participants (Anticipated)Interventional2013-01-28Recruiting
A Randomized, Double-Blind, Active Control, 5 Week Study to Evaluate the Safety and Skin Effects of A New, Twice-daily, Topically Applied Amino Acid Moisturizing Cream vs. Desonide Cream in Adult Atopic Dermatitis [NCT02286700]Phase 342 participants (Anticipated)Interventional2014-11-30Recruiting
Efficacy and Tolerability of New Topical Formulations in Subjects With Atopic Dermatitis [NCT02732314]Phase 453 participants (Actual)Interventional2016-03-31Completed
Proton Pump Inhibitors Use in Patients With Psoriasis [NCT02624544]Phase 40 participants (Actual)Interventional2016-01-31Withdrawn(stopped due to Sponsor decision)
Efficacy of the V0034CR01B Emollient on Xerosis in Children With Atopic Dermatitis. Randomised, Vehicle-controlled, Parallel-groups, Double-blind Study With an Open Label Extension. [NCT01467362]Phase 3251 participants (Actual)Interventional2011-11-30Completed
A Randomized, Evaluator Blinded, Within Subject, Single-Centre Evaluation of the Vasoconstriction Properties of MC2-01 Cream, Compared to 5 Other Corticosteroids in Healthy Subjects [NCT03758365]Phase 136 participants (Actual)Interventional2018-11-05Completed
A Double Blind, Randomized Clinical Trial of 4% Niacinamide Versus 0.05% Desonide for the Treatment of Axillar Hyperpigmentation [NCT01542138]Phase 428 participants (Actual)Interventional2011-07-31Completed
Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis [NCT00690833]Phase 441 participants (Actual)Interventional2007-08-31Completed
Emollients in the Management of Atopic Dermatitis in Children: Prevention of Flares. [NCT01779258]Phase 3347 participants (Actual)Interventional2013-02-28Completed
A Randomized, Investigator-Blind, Six-Week, Parallel Group, Multicenter Pilot Study to Compare the Safety and Efficacy of EpiCeram Skin Barrier Emulsion and Desonide Cream 0.05% in the Twice Daily Treatment of Pediatric Subjects With Moderate Atopic Derma [NCT00828412]Phase 4100 participants (Actual)Interventional2009-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00690833 (1) [back to overview]Investigator Global Assessment at Week 4
NCT00828412 (1) [back to overview]Change From Baseline in Three Item Severity Score
NCT03386032 (2) [back to overview]Severity Scoring of Atopic Dermatitis (SCORAD) Amongst Subjects With Moderate Atopic Dermatitis
NCT03386032 (2) [back to overview]Severity Scoring of Atopic Dermatitis (SCORAD) Amongst Subjects With Severe Atopic Dermatitis
NCT03758365 (2) [back to overview]Comparison of the Vasoconstriction Potential (Skin Blanching Effect) of the MC2-01 Cream With Active Comparators and Vehicle
NCT03758365 (2) [back to overview]Compare Local Tolerability of the MC2-01 Cream With Active Comparators and Vehicle

Investigator Global Assessment at Week 4

The Investigator global assessment at Week 4 is based on an overall scale of 0-4 with 0 being clear and 4 being very severe (NCT00690833)
Timeframe: Week 4

Interventionunits on a scale (Mean)
Topical Desonide Hydrogel 0.05%2.3

[back to top]

Change From Baseline in Three Item Severity Score

The average of the sum of scores for erythema, edema/papulation, and excoriation for two target lesions. Scoring on a scale of 0 to 3 (none to severe). Maximum score is 9. (NCT00828412)
Timeframe: Baseline to 6 weeks

Interventionunits on a scale (Mean)
EpiCeram Skin Barrier Emulsion-2.6
Desonide Cream 0.05%-3.6

[back to top]

Severity Scoring of Atopic Dermatitis (SCORAD) Amongst Subjects With Moderate Atopic Dermatitis

"SCORAD (Severity Scoring of Atopic Dermatitis) Change from Baseline to Week 8 of atopic dermatitis lesion as measured by the Scoring of Atopic Dermatitis (SCORAD). SCORAD is a composite severity index comprising a) the amount/extent of body area affected; b)b) 2 subjective symptom of pruritus (10 pts VAS) and sleep disturbance measured (10 pts VAS); and c) 6 disease intensity assessments [Dryness/Scaling, Erythema, Excoriation, Induration/Papulation, Lichenification and Oozing/ Weeping/Crusting, each graded in 3pts TIS from 0 (None) to 3 (Severe). A SCORAD score ranges from 0 (No AD present) to 103~SCORAD is calculated:~Extent 7*Intensity SCORAD = --------- + ---------------- + Subjective 5 2" (NCT03386032)
Timeframe: Baseline to Week 8

Interventionunits on a scale (Mean)
Investigational OTC Cream-12.2
Placebo Cream9.3
0.05% Desonide Cream-17.5

[back to top]

Severity Scoring of Atopic Dermatitis (SCORAD) Amongst Subjects With Severe Atopic Dermatitis

"SCORAD (Severity Scoring of Atopic Dermatitis) Change from Baseline to Week 8 of atopic dermatitis lesion as measured by the Scoring of Atopic Dermatitis (SCORAD). SCORAD is a composite severity index comprising a) the amount/extent of body area affected; b)b) 2 subjective symptom of pruritus (10 pts VAS) and sleep disturbance measured (10 pts VAS); and c) 6 disease intensity assessments [Dryness/Scaling, Erythema, Excoriation, Induration/Papulation, Lichenification and Oozing/ Weeping/Crusting, each graded in 3pts TIS from 0 (None) to 3 (Severe). A SCORAD score ranges from 0 (No AD present) to 103~SCORAD is calculated:~Extent 7*Intensity SCORAD = --------- + ---------------- + Subjective 5 2" (NCT03386032)
Timeframe: Baseline to Week 8

Interventionunits on a scale (Mean)
Investigational OTC Cream-6.0
Placebo Cream-20.3
0.05% Desonide Cream-18.0

[back to top]

Comparison of the Vasoconstriction Potential (Skin Blanching Effect) of the MC2-01 Cream With Active Comparators and Vehicle

Blanching of the skin will be assessed individually by two trained observers blinded to treatment. The observers will score the blanching of the skin from 0-4 (0 = No change in color skin; 1 = Slight (barely visible) blanching; 3 = Obvious blanching; 4 = Blanching judged to be maximal). The results is presented as Mean ± SD. (NCT03758365)
Timeframe: Day 2

Interventionscore on a scale (Mean)
MC2-01 CreamClobetasol Propionate 0.05% LotionBetamethasone Dipropionate 0.05% CreamTriamcinolone Acetonide 0.1% CreamHydrocortisone Butyrate 0.1% CreamDesonide 0.05% CreamVehicle Cream
MC2-01 Cream + Comparators1.663.052.451.922.062.110.14

[back to top]

Compare Local Tolerability of the MC2-01 Cream With Active Comparators and Vehicle

The local tolerability of the creams will be assesed using a predefined scale: 0 = No reaction; 0.5 = Only slight erythema; 1 = Only erythema; 2 = Erythema with papules or oedema; 3 = Erythema, oedema with papules, oedema with vesicle; 4 = Blisters (NCT03758365)
Timeframe: Day 2

InterventionParticipants (Count of Participants)
MC2-01 Cream72211385Clobetasol Propionate 0.05% Lotion72211385Betamethasone Dipropionate 0.05% Cream72211385Triamcinolone Acetonide 0.1% Cream72211385Hydrocortisone Butyrate 0.1% Cream72211385Desonide 0.05% Cream72211385Vehicle Cream72211385
Erythema with papules or oedemaNo reactionOnly Slight reactionOnly erythemaErythema, oedema with papules, oedema with vesicleBlisters
MC2-01 Cream + Comparators0
MC2-01 Cream + Comparators36

[back to top]